<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>jmedicalcasereports</PublisherName>
<JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Volume 6; Issue 6</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>(Nov-Dec, 2025)</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Medical Case Reports</ArticleType>
<ArticleTitle>High-Grade Serous Carcinoma of The Thoracic Wall: A Primary Tumor Associated with Serous Tubal Intraepithelial Carcinoma</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1</FirstPage>
<LastPage>11</LastPage>
<AuthorList>
<Author>
<FirstName>Liapi</FirstName>
<LastName>Aikaterini</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Hastir</FirstName>
<LastName>Delfyne</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Lelievre</FirstName>
<LastName>Loic</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Sarivalasis</FirstName>
<LastName>Apostolos</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>High-grade serous carcinomas (HGSC) are aggressive neoplasms arising frequently from the uterine, ovarian, fallopian tube or peritoneal epithelium. They are characterized by aberrant p53 expression and rapid clinical evolution with early peritoneal and metastatic spread. Serous tubal intraepithelial carcinoma (STIC) is considered the precursor lesion of high-grade serous ovarian carcinoma (HGSOC), the most common subtype of ovarian cancer. High-grade serous carcinomas’ main spreading pattern is through peritoneal fluid to distant peritoneal invasive localization, resulting in peritoneal carcinomatosis. Occasionally, HGSC can metastasize through lymphovascular invasions to lymph nodes and other peritoneal and extra peritoneal organs. High grade serous carcinoma metastases of the thoracic wall with extensive local and mediastinal lymph-node invasion, lacking peritoneal, abdominal or gynecological primary invasive tumor, is a rare clinical situation. In this report, we present the case of a 68 year-old female patient’s HGSC, with extensive thoracic wall infiltration and extra peritoneal-only metastases. Interestingly, the diagnostic laparoscopy with hysterectomy and bilateral annexectomy ruled out peritoneal metastasis and invasive disease, detecting STIC sites.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Pleural High-Grade Serous Carcinoma,STIC Associated with Distant Thoracic Metastasis,STIC Without Ovarian or Peritoneal Invasive Spread</Keywords>
<URLs>
<Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=16038&title=High-Grade Serous Carcinoma of The Thoracic Wall: A Primary Tumor Associated with Serous Tubal Intraepithelial Carcinoma</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26: 4160-4165.
Fukumura Y, Masaoka A, Naito T, Kimura M, Yao T. A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report. Diagn Pathol 2009; 4: 43.
Horn LC, Kafkova S, Leonhardt K, Kellner C, Einenkel J. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. Int J Gynecol Pathol 2013; 32: 339-344.
Itamochi H, Shoji T, Sugiyama T, Mukaida R, Sasou S, Takeshita R, Sato T. A Case of High-Grade Serous Tubal Intraepithelial Carcinoma Diagnosed with Adenocarcinoma by Ascitic Fluid Cytology. Journal of Tumor 2017; 5: 488-491.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IeM. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
Nasser S, Fotopoulou C, Richter R, Kaulich J, Braicu E, Beteta C, Olschewski J, Babayeva A, Sehouli J. Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer. Anticancer Res 2021; 41: 2033-2038.
Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open 2021; 6: 100144.
Otsuka I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. Int J Mol Sci 2021; 22: 4409.
Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013; 119: 332-328.
Ray-Coquard I, Pautier P, Pignata S, Pand;eacute;rol D, Gonzand;aacute;lez-Martand;iacute;n A, Berger R, Fujiwara K, Vergote I, Colombo N, Mand;auml;enpand;auml;and;auml; J, Selle F, Sehouli J, Lorusso D, Guerra Aland;iacute;a EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmand;eacute; F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 2019; 381: 2416-2428.
Rogers R, Ehmann S, Tew WP, Broach V. Isolated splenic high-grade serous carcinoma: A case report. Gynecol Oncol Rep 2021; 37: 100818.
Schneider S, Heikaus S, Harter P, Heitz F, Grimm C, Ataseven B, Prader S, Kurzeder C, Ebel T, Traut A, du Bois A. Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. Int J Gynecol Cancer 2017; 27: 444-451.
Shih LC, Li WS, Tsai SC, Ke YM, Hsu ST, Huang SF, Chou MM, Lu CH. Primary serous tubal intraepithelial carcinoma with multiple lymph node metastases. Taiwan J Obstet Gynecol 2016; 55: 609-612.
Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T. Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report. Diagn Pathol 2019; 14: 17.
Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013; 23: 1603-1611.</References>
</References>
</Journal>
</Article>
</ArticleSet>